Abstract
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known in mediating the toxicities of dioxins and dioxin-like compounds. AHR is activated by a variety of endogenous ligands and participating in tumor development. Thus, it will provide a new approach for cancer prevention and treatment to study the translation mechanism of AHR in tumor cells. In this study, we show that the 5'-untranslated region (UTR) of AHR mRNA contains an internal ribosome entry site (IRES). After mapping the entire AHR 5'-UTR, we determined that the full-length 5'-UTR is indispensable for the highest IRES activity. Interestingly, we found that AHR expression is induced in ovarian (A2780), breast (MDA-MB231), hepatic (Bel7402) and colorectal cancer cells (SW620) by chemotherapeutic drug paclitaxel (PTX) through IRES-dependent translation mechanism. Moreover, IRES activity is increased in the PTX-resistant ovarian cancer cells in which AHR protein expression was also enhanced. These results strongly suggest an important role for AHR IRES-dependent translation mechanism in cancer cell response to paclitaxel treatment.
Introduction
The Aryl Hydrocarbon Receptor (AHR) is a transcription factor notorious for helping cancer cells invade, migrate, and survive. While scientists knew that AHR levels are often high in tumors, they primarily focused on how the AHR gene is turned on (transcription). However, when cancer cells are under extreme stress—such as during chemotherapy—the standard machinery for making proteins (cap-dependent translation) usually shuts down to save energy. Despite this, AHR levels often remain high or even increase. This paper investigates the "how": is there a hidden mechanism in the AHR mRNA that allows it to bypass the standard cellular shutdown and continue producing protein during drug-induced stress?
Structural Basis for AHR Translation
The AHR mRNA has an unusually long 5'-UTR (613 bases) with eight distinct "stem-loop" structures. In molecular biology, this complex "tangle" at the start of an mRNA is a classic sign that it might harbor an Internal Ribosome Entry Site (IRES). This specialized "backdoor" allows the ribosome to bind directly to the mRNA, bypassing the need for the standard 5' cap structure that is often compromised during cellular stress.
Experimental Validation and Mapping
To confirm the presence of an IRES, researchers employed dicistronic reporter assays, the "gold standard" for detecting such activity. By creating DNA constructs with two different fluorescent reporter genes, they proved that the ribosome could initiate translation in the middle of the mRNA. Systematic deletion mapping further revealed that the region between nucleotides -404 and -313 is indispensable for maximal IRES activity.
Crucially, the study found that the AHR IRES is remarkably powerful, showing 3.2 times higher activity than the well-characterized IRES found in NRF mRNA. This efficiency explains why AHR protein levels can increase even when global translation is suppressed.
Impact on Cancer Cell Survival and Drug Resistance
The functional significance of AHR was demonstrated through siRNA knockdown experiments across multiple cell lines, including ovarian (A2780), breast (MDA-MB231), and colorectal (SW620) cancer cells. Silencing AHR significantly reduced cell growth and triggered apoptosis, as evidenced by increased levels of the pro-apoptotic marker Caspase-3 and decreased levels of the anti-apoptotic protein Survivin.
When cells were treated with Paclitaxel (PTX), AHR protein levels rose while mRNA levels remained stable, confirming that the regulation occurs at the translational level. Furthermore, PTX-resistant ovarian cancer cells exhibited significantly higher IRES activity (~1.67-fold increase) compared to sensitive cells, suggesting that this mechanism is a key survival strategy used by tumors to evade chemotherapy.
Conclusion and Future Directions
This study identifies a novel IRES-dependent mechanism for AHR translation that is activated by paclitaxel treatment. While the existence of the IRES is clear, future work is needed to identify the specific helper proteins (ITAFs) that facilitate this process. Additionally, moving from in vitro cell cultures to animal models and clinical samples will be essential to determine if targeting the AHR IRES can serve as a viable therapeutic strategy to overcome drug resistance in cancer patients.
Summary updated